Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Liabilities and Shareholders Equity (2017 - 2025)

Cue Biopharma (CUE) has disclosed Liabilities and Shareholders Equity for 9 consecutive years, with $42.2 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 31.13% to $42.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $136.8 million through Dec 2025, down 21.04% year-over-year, with the annual reading at $42.2 million for FY2025, 31.13% up from the prior year.
  • Liabilities and Shareholders Equity hit $42.2 million in Q4 2025 for Cue Biopharma, up from $31.6 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $91.3 million in Q4 2022 to a low of $22.3 million in Q1 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $64.0 million across 5 years, with a median of $71.0 million in 2023.
  • Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 46.29% in 2021 and later plummeted 58.75% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $83.4 million in 2021, then rose by 9.45% to $91.3 million in 2022, then tumbled by 32.59% to $61.5 million in 2023, then crashed by 47.68% to $32.2 million in 2024, then surged by 31.13% to $42.2 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for CUE at $42.2 million in Q4 2025, $31.6 million in Q3 2025, and $40.7 million in Q2 2025.